Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy

Acta Biomaterialia

Volumn 7, Issue 10, 2011, Pages 3656-3669

  Parhi, Priyambada ^a   Mohanty, Chandana ^a   Sahoo, Sanjeeb Kumar ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Apoptosis; Bioavailability; Biocompatibility; Cubic phase nanoparticles; Rapamycin

Indexed keywords

BIOCHEMISTRY; CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; DISEASES; EMULSIFICATION; MAMMALS; NANOPARTICLES; ONCOLOGY; TARGETED DRUG DELIVERY; TOXICITY;

CANCER THERAPY; CELLULAR UPTAKE; CUBIC NANOPARTICLES; CUBIC PHASE; CUBIC PHASE NANOPARTICLE; HIGH RATE; IN-VIVO; PRECLINICAL STUDIES; RAPAMYCIN; VIVO PHARMACOKINETICS;

BIOCOMPATIBILITY;

ALPHA TOCOPHEROL; MACROGOL 10000; NANOPARTICLE; RAPAMYCIN; SUCCINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG UPTAKE; FLOW CYTOMETRY; FOURIER TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; X RAY DIFFRACTION; ZETA POTENTIAL;

AGOUTI PACA; MAMMALIA;

EID: 80052267870     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2011.06.015     Document Type: Article

References (55)

1. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 2004 335 348 (Pubitemid 38579480)
2. J.B. Easton, and P.J. Houghton MTOR and cancer therapy Oncogene 25 2006 6436 6446 (Pubitemid 44582287)
3. M. Hidalgo, and E.K. Rowinsky The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 2000 6680 6686 (Pubitemid 32197708)
4. S. Muthukkumar, T.M. Ramesh, and S. Bondada Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells Transplantation 60 1995 264 270
5. T. Seufferlein, and E. Rozengurt Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells Cancer Res 56 1996 3895 3897 (Pubitemid 26284735)
6. H. Hosoi, M.B. Dilling, T. Shikata, L.N. Liu, L. Shu, and R.A. Ashmun Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells Cancer Res 59 1999 886 894 (Pubitemid 29086744)
7. S. Huang, L. Shu, M.B. Dilling, J. Easton, F.C. Harwood, and H. Ichijo Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1) Mol Cell 11 2003 1491 1501 (Pubitemid 36776536)
8. P. Simamora, J.M. Alvarez, and S.H. Yalkowsky Solubilization of rapamycin Int J Pharm 213 2001 25 29 (Pubitemid 32119459)
9. K.L. Napoli, M.E. Wang, S.M. Stepkowski, and B.D. Kahan Distribution of sirolimus in rat tissue Clin Biochem 30 1997 135 142 (Pubitemid 27180926)
10. R. Misra, S. Acharya, F. Dilnawaz, and S.K. Sahoo Sustained antibacterial activity of doxycycline-loaded poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles Nanomedicine (Lond.) 4 2009 519 530
11. S.K. Sahoo, and V. Labhasetwar Nanotech approaches to drug delivery and imaging Drug Discov Today 8 2003 1112 1120 (Pubitemid 37547917)
12. S.K. Sahoo, S. Parveen, and J.J. Panda The present and future of nanotechnology in human health care Nanomedicine 3 2007 20 31 (Pubitemid 46428187)
13. M.M. Borner, P. Schoffski, R. de Wit, F. Caponigro, G. Comella, and A. Sulkes Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer Eur J Cancer 38 2002 349 358 (Pubitemid 34121962)
14. J. von Pawel, U. Gatzemeier, J.L. Pujol, L. Moreau, S. Bildat, and M. Ranson Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer J. Clin. Oncol. 19 2001 1743 1749 (Pubitemid 32230876)
15. S.S. Feng, L. Mu, K.Y. Win, and G. Huang Nanoparticles of biodegradable polymers for clinical administration of paclitaxel Curr Med Chem 11 2004 413 424 (Pubitemid 38294346)
16. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J Biotechnol 113 2004 151 170 (Pubitemid 39237077)
17. V. Wagner, A. Dullaart, A.K. Bock, and A. Zweck The emerging nanomedicine landscape Nat Biotechnol 24 2006 1211 1217 (Pubitemid 44564760)
18. S. Bisht, G. Feldmann, J.B. Koorstra, M. Mullendore, H. Alvarez, and C. Karikari In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities Mol Cancer Ther 7 2008 3878 3888
19. P. Spicer Cubosomes: bicontinuous cubic liquid crystalline nanostructured particles Encyclopedia of nanoscience and nanotechnology 2003 Marcel Dekker New York 881 892
20. F. Dilnawaz, A. Singh, C. Mohanty, and S.K. Sahoo Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy Biomaterials 31 2010 3694 3706
21. S. Ganguly, and A.K. Dash A novel in situ gel for sustained drug delivery and targeting Int J Pharm 276 2004 83 92 (Pubitemid 38542991)
22. C. Mohanty, and S.K. Sahoo The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation Biomaterials 31 2010 6597 6611
23. A. Singh, F. Dilnawaz, S. Mewar, U. Sharma, N.R. Jagannathan, and S.K. Sahoo Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy ACS Appl Mater Interfaces 3 2011 842 856
24. M. Das, C. Mohanty, and S.K. Sahoo Ligand-based targeted therapy for cancer tissue Expert Opin. Drug Deliv. 6 2009 285 304
25. A.V. Kabanov, P. Lemieux, S. Vinogradov, and V. Alakhov Pluronic block copolymers: novel functional molecules for gene therapy Adv Drug Deliv Rev 54 2002 223 233 (Pubitemid 34230443)
26. Z. Zhang, and S.S. Feng Self-assembled nanoparticles of poly(lactide)-vitamin E TPGS copolymers for oral chemotherapy Int J Pharm 324 2006 191 198 (Pubitemid 44550164)
27. E.M. Collnot, C. Baldes, M.F. Wempe, J. Hyatt, L. Navarro, and K.J. Edgar Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers J. Control. Release 111 2006 35 40 (Pubitemid 43289992)
28. Y.L. Lo Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines J. Control. Release 90 2003 37 48
29. S.K. Sahoo, W. Ma, and V. Labhasetwar Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer Int. J. Cancer 112 2004 335 340 (Pubitemid 39244375)
30. J. Panyam, S.K. Sahoo, S. Prabha, T. Bargar, and V. Labhasetwar Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L-lactide-co-glycolide) nanoparticles Int J Pharm 262 2003 1 11 (Pubitemid 36966688)
31. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 2009 5737 5750
32. C. Mohanty, S. Acharya, A.K. Mohanty, F. Dilnawaz, and S.K. Sahoo Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy Nanomedicine (Lond.) 5 2010 433 449
33. M. Das, and S.K. Sahoo Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy Acta Biomater 7 2010 355 369
34. S. Parveen, M. Mitra, S. Krishnakumar, and S.K. Sahoo Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line Acta Biomater 6 2010 3120 3131
35. S. Zhang, J. Salemi, H. Hou, Y. Zhu, T. Mori, and B. Giunta Rapamycin promotes beta-amyloid production via ADAM-10 inhibition Biochem Biophys Res Commun 398 2010 337 341
36. S.S. Feng, L. Mei, P. Anitha, C.W. Gan, and W. Zhou Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel Biomaterials 30 2009 3297 3306
37. W.J. Trickler, A.A. Nagvekar, and A.K. Dash A novel nanoparticle formulation for sustained paclitaxel delivery AAPS PharmSciTech 9 2008 486 493
38. S. Qanungo, M. Das, S. Haldar, and A. Basu Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells Carcinogenesis 26 2005 958 967 (Pubitemid 41214325)
39. M. Vandana, and S.K. Sahoo Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles Nanomedicine (Lond.) 4 2009 773 785
40. F. Vega, L.J. Medeiros, V. Leventaki, C. Atwell, J.H. Cho-Vega, and L. Tian Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma Cancer Res 66 2006 6589 6597 (Pubitemid 44085614)
41. R. Misra, and S.K. Sahoo Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy Eur J Pharm Sci 39 2010 152 163
42. K.Y. Win, and S.S. Feng Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2005 2713 2722
43. A.G. Tkachenko, H. Xie, D. Coleman, W. Glomm, J. Ryan, and M.F. Anderson Multifunctional gold nanoparticle-peptide complexes for nuclear targeting J Am Chem Soc 125 2003 4700 4701 (Pubitemid 36505350)
44. W.J. Trickler, A.A. Nagvekar, and A.K. Dash The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel Pharm Res 26 2009 1963 1973
45. P.J. Costanzo, T.E. Patten, and T.A. Seery Nanoparticle agglutination: acceleration of aggregation rates and broadening of the analyte concentration range using mixtures of various-sized nanoparticles Langmuir 22 2006 2788 2794
46. S.K. Sahoo, and V. Labhasetwar Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention Mol Pharm 2 2005 373 383 (Pubitemid 41503678)
47. C.D. Bortner, and J.A. Cidlowski Caspase independent/dependent regulation of K(+), cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis J Biol Chem 274 1999 21953 21962
48. D.R. Green, and J.C. Reed Mitochondria and apoptosis Science 281 1998 1309 1312 (Pubitemid 28406816)
49. H.L. Kenerson, L.D. Aicher, L.D. True, and R.S. Yeung Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors Cancer Res 62 2002 5645 5650 (Pubitemid 35204715)
50. M.G. Schlieman, B.N. Fahy, R. Ramsamooj, L. Beckett, and R.J. Bold Incidence, mechanism and prognostic value of activated AKT in pancreas cancer Br J Cancer 89 2003 2110 2115 (Pubitemid 38030911)
51. J. Averous, and C.G. Proud When translation meets transformation: the mTOR story Oncogene 25 2006 6423 6435 (Pubitemid 44582286)
52. M. Rosner, and M. Hengstschlager Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1 Hum Mol Genet 17 2008 2934 2948
53. M.J. Hawkins, P. Soon-Shiong, and N. Desai Protein nanoparticles as drug carriers in clinical medicine Adv Drug Deliv Rev 60 2008 876 885
54. W.W. Ma, and A. Jimeno Temsirolimus Drugs Today (Barc.) 43 2007 659 669 (Pubitemid 350220790)
55. P. Smolewski Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway Anticancer Drugs 17 2006 487 494 (Pubitemid 44309964)